In another study, an HDAC6-selective inhibitor, St.17 (Table 2), was developed through a SAR approach for the treatment of T-cell prolymphocytic leukemia (T-PLL), an aggressive and currently incurable hematological malignancy. This evidence concerns the gene HDAC6 and T-cell prolymphocytic leukemia.